Published Date: 16 Mar 2023
Avascular necrosis (AVN) is considered an iatrogenic complication after treatment for progressive hip dysplasia, but research in China has revealed two characteristics associated with this condition. ossification nuclei.
Read Full NewsFrontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Fear of Movement, Central Sensitization May Worsen Outcomes in Gout
FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026
FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease
Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life
1.
The most precise research tools for the deadliest blood cancer have been developed.
2.
Eight Doctors Killed in Brazil's Horrifying Plane Crash
3.
Discovery of estrogen receptor 'switches' may aid breast cancer treatment
4.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
5.
FDA Expands Durvalumab Label to Operable Lung Cancer
1.
Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds
2.
Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
5.
Unlocking the Secrets of Leukemic Stem Cells: A Path to Better Blood Cancer Treatments
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
5.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation